MA31202B1 - Procede de traitement du cancer - Google Patents

Procede de traitement du cancer

Info

Publication number
MA31202B1
MA31202B1 MA32188A MA32188A MA31202B1 MA 31202 B1 MA31202 B1 MA 31202B1 MA 32188 A MA32188 A MA 32188A MA 32188 A MA32188 A MA 32188A MA 31202 B1 MA31202 B1 MA 31202B1
Authority
MA
Morocco
Prior art keywords
way
treat cancer
mammal
human
effective amount
Prior art date
Application number
MA32188A
Other languages
Arabic (ar)
English (en)
Inventor
Connie Lynn Erickson-Miller
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39690807&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA31202(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of MA31202B1 publication Critical patent/MA31202B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne un procédé de traitement du cancer et des syndromes précancéreux chez un mammifère, y compris chez un être humain en ayant besoin, qui comprend l'administration d'une quantité thérapeutiquement efficace d'un agoniste de récepteur de tpo non-peptidique à un tel mammifère.
MA32188A 2007-02-16 2009-08-31 Procede de traitement du cancer MA31202B1 (fr)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US89023607P 2007-02-16 2007-02-16
US89255207P 2007-03-02 2007-03-02
US90820507P 2007-03-27 2007-03-27
US94934707P 2007-07-12 2007-07-12
US95228907P 2007-07-27 2007-07-27
US96919207P 2007-08-31 2007-08-31
US97721607P 2007-10-03 2007-10-03
PCT/US2008/054046 WO2008101141A2 (fr) 2007-02-16 2008-02-15 Procédé de traitement du cancer

Publications (1)

Publication Number Publication Date
MA31202B1 true MA31202B1 (fr) 2010-02-01

Family

ID=39690807

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32188A MA31202B1 (fr) 2007-02-16 2009-08-31 Procede de traitement du cancer

Country Status (28)

Country Link
US (2) US20100075928A1 (fr)
EP (1) EP2124547B3 (fr)
JP (1) JP5511391B2 (fr)
KR (1) KR101447763B1 (fr)
CN (1) CN101662937B (fr)
AR (1) AR065348A1 (fr)
AU (1) AU2008216106C1 (fr)
BR (1) BRPI0807940B8 (fr)
CA (1) CA2678358C (fr)
CR (1) CR10997A (fr)
DK (1) DK2124547T6 (fr)
EA (1) EA017715B1 (fr)
ES (1) ES2675070T7 (fr)
FI (1) FI2124547T4 (fr)
HU (1) HUE038563T2 (fr)
IL (2) IL200319A (fr)
MA (1) MA31202B1 (fr)
MX (1) MX2009008822A (fr)
NZ (1) NZ579068A (fr)
PE (1) PE20081784A1 (fr)
PL (1) PL2124547T5 (fr)
PT (1) PT2124547T (fr)
SI (1) SI2124547T2 (fr)
TR (1) TR201809010T4 (fr)
TW (1) TW200906393A (fr)
UY (1) UY30915A1 (fr)
WO (1) WO2008101141A2 (fr)
ZA (1) ZA200905532B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110160130A1 (en) * 2007-02-16 2011-06-30 Connie Erickson-Miller Cancer treatment method
US20110129550A1 (en) * 2007-02-16 2011-06-02 Connie Erickson-Miller Cancer treatment method
ECSP077628A (es) 2007-05-03 2008-12-30 Smithkline Beechman Corp Nueva composición farmacéutica
CN101888841B (zh) * 2007-10-09 2012-09-26 宾夕法尼亚大学理事会 血小板生成素受体激动剂(TpoRA)杀死急性人骨髓样白血病细胞
CA2763768A1 (fr) 2009-05-29 2010-12-02 Glaxosmithkline Llc Procedes d'administration de composes agonistes de la thrombopoietine
JP2013538810A (ja) * 2010-09-01 2013-10-17 ノバルティス アーゲー Ｈｄａｃ阻害剤と血小板減少症薬との組合せ
US9962370B2 (en) 2013-03-15 2018-05-08 Ligand Pharmaceuticals Incorporated Methods of treatment associated with the granulocyte colony-stimulating factor receptor
SG10201913416PA (en) * 2016-05-06 2020-03-30 Taris Biomedical Llc Method of treating lower tract urothelial cancer
RU2675695C1 (ru) * 2018-03-06 2018-12-24 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии имени Н.Н. Петрова" Министерства здравоохранения Российской Федерации Способ лечения рака предстательной железы высокого и очень высокого риска

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559235A (en) 1991-10-29 1996-09-24 Glaxo Wellcome Inc. Water soluble camptothecin derivatives
US5342947A (en) * 1992-10-09 1994-08-30 Glaxo Inc. Preparation of water soluble camptothecin derivatives
AP9300587A0 (en) * 1992-11-12 1995-05-05 Glaxo Inc Water soluble camptothecin derivatives.
US5681835A (en) * 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US5491237A (en) * 1994-05-03 1996-02-13 Glaxo Wellcome Inc. Intermediates in pharmaceutical camptothecin preparation
US6316652B1 (en) * 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
WO1999011262A1 (fr) 1997-09-02 1999-03-11 Roche Diagnostics Gmbh Ligands du recepteur mpl, leur procede de preparation, medicaments les contenant et leur utilisation pour le traitement et la prevention de la thrombocytopenie et l'anemie
US7026334B1 (en) * 1999-07-26 2006-04-11 Shionogi & Co., Ltd. Thiazolidine compounds and pharmaceutical compositions exhibiting thrombopoietin receptor agonism
EP2087907B1 (fr) * 1999-11-10 2014-09-24 Innatus Corporation Procédé et système pour supprimer l'inhibiteur de cytokine chez les patients
EP1104674A1 (fr) 1999-11-10 2001-06-06 Curacyte AG Colorants o-o'-dihydroxy azoiques dans des médicaments ayant une activité TPO-agoniste ou synergétique
TWI284639B (en) 2000-01-24 2007-08-01 Shionogi & Co A compound having thrombopoietin receptor agonistic effect
CY2010012I2 (el) * 2000-05-25 2020-05-29 Novartis Ag Μιμητικα θρομβοποιητινης
JP3966816B2 (ja) * 2000-05-30 2007-08-29 中外製薬株式会社 トロンボポエチン様活性を有する化合物
EP1284997B1 (fr) * 2000-05-31 2005-04-06 Genzyme Corporation Composes therapeutiques contre le cancer des ovaires
DE60203260T2 (de) * 2001-01-16 2006-02-02 Glaxo Group Ltd., Greenford Pharmazeutische kombination, die ein 4-chinazolinamin und paclitaxel, carboplatin oder vinorelbin enthält, zur behandlung von krebs
CA2435143A1 (fr) 2001-01-26 2002-08-01 Shionogi & Co., Ltd. Composes halogene ayant un agonisme envers le recepteur de thrombopoietine
US7169931B2 (en) 2001-01-26 2007-01-30 Shionogi & Co., Ltd. Cyclic compounds exhibiting thrombopoietin receptor agonism
WO2002062775A1 (fr) 2001-02-02 2002-08-15 Yamanouchi Pharmaceutical Co., Ltd. Dérivé de 2-acylaminothiazole ou son sel
US6613753B2 (en) * 2001-02-21 2003-09-02 Supergen, Inc. Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation
PL370867A1 (en) * 2001-09-24 2005-05-30 Tosk, Inc. Reduced toxicity cisplatin formulations and methods for using the same
ES2610611T3 (es) * 2002-01-18 2017-04-28 Astellas Pharma Inc. Derivado de 2-acilaminotiazol o sal del mismo
AR040083A1 (es) * 2002-05-22 2005-03-16 Smithkline Beecham Corp Compuesto bis-(monoetanolamina) del acido 3'-[(2z)-[1-(3,4-dimetilfenil) -1,5-dihidro-3-metil-5-oxo-4h-pirazol-4-iliden] hidrazino] -2'-hidroxi-[1,1'-bifenil]-3-carboxilico, procedimiento para prepararlo, composicion farmaceutica que lo comprende, procedimiento para preparar dicha composicion farmac
WO2004029049A1 (fr) * 2002-09-30 2004-04-08 Yamanouchi Pharmaceutical Co., Ltd. Nouveau sel d'un derive de 2-acylaminothiazole
WO2004096154A2 (fr) 2003-04-29 2004-11-11 Smithkline Beecham Corporation Procedes de traitement de maladies/lesions degeneratives
WO2005118551A2 (fr) * 2004-05-28 2005-12-15 Ligand Pharmaceuticals Inc. Composes modulant l'activite de la thrombopoietine et methodes associees
CA2583764C (fr) * 2004-10-25 2009-06-09 Ligand Pharmaceuticals, Inc. Composes et methodes visant a reguler l'activite de la thrombopoietine
BRPI0620532A2 (pt) 2005-11-23 2011-11-16 Ligand Pharm Inc compostos e métodos para modular a atividade de trombopoietina
US20100063301A1 (en) 2006-03-15 2010-03-11 Ligand Pharmaceuticals Inc Synthesis of thrombopoietin activity modulating compounds

Also Published As

Publication number Publication date
UY30915A1 (es) 2008-09-02
AU2008216106C1 (en) 2025-11-13
IL238394A0 (en) 2015-06-30
MX2009008822A (es) 2009-08-28
IL238394B (en) 2018-05-31
WO2008101141A2 (fr) 2008-08-21
TR201809010T4 (tr) 2018-07-23
CN101662937B (zh) 2014-03-12
EP2124547A2 (fr) 2009-12-02
CN101662937A (zh) 2010-03-03
CA2678358C (fr) 2015-12-08
WO2008101141A3 (fr) 2008-10-16
EP2124547B3 (fr) 2025-06-18
NZ579068A (en) 2012-05-25
DK2124547T3 (en) 2018-07-16
EP2124547B2 (fr) 2025-04-16
EA200970776A1 (ru) 2010-02-26
TW200906393A (en) 2009-02-16
EP2124547B1 (fr) 2018-03-28
SI2124547T2 (sl) 2025-07-31
IL200319A0 (en) 2010-04-29
KR101447763B1 (ko) 2014-10-07
FI2124547T4 (fi) 2025-07-29
PL2124547T5 (pl) 2025-08-04
CA2678358A1 (fr) 2008-08-21
BRPI0807940B8 (pt) 2021-05-25
AR065348A1 (es) 2009-06-03
US20100075928A1 (en) 2010-03-25
BRPI0807940A2 (pt) 2013-07-30
BRPI0807940B1 (pt) 2020-10-27
KR20090113330A (ko) 2009-10-29
US20090022814A1 (en) 2009-01-22
PE20081784A1 (es) 2009-01-25
ES2675070T7 (en) 2025-08-06
ZA200905532B (en) 2010-04-28
AU2008216106A1 (en) 2008-08-21
IL200319A (en) 2015-05-31
DK2124547T6 (da) 2025-09-01
DK2124547T4 (da) 2025-08-04
HUE038563T2 (hu) 2018-10-29
EA017715B1 (ru) 2013-02-28
AU2008216106B2 (en) 2013-07-11
AU2008216106B9 (en) 2013-09-05
EP2124547A4 (fr) 2010-05-05
JP2010519221A (ja) 2010-06-03
CR10997A (es) 2009-10-16
PL2124547T3 (pl) 2018-08-31
JP5511391B2 (ja) 2014-06-04
PT2124547T (pt) 2018-07-04
SI2124547T1 (en) 2018-08-31
ES2675070T3 (es) 2018-07-06

Similar Documents

Publication Publication Date Title
MA31202B1 (fr) Procede de traitement du cancer
MA32132B1 (fr) Utilisation de ranolazine pour traiter la douleur
EA201690111A1 (ru) Имидазопиразиновые ингибиторы тирозинкиназы syk
EP2103628A4 (fr) Anticorps monoclonal anti-claudine 3, et traitement et diagnostic du cancer au moyen d&#39;un tel anticorps
EA201190043A1 (ru) Имидазопиразиновые ингибиторы syk
SG164369A1 (en) Human anti-b7rp1 neutralizing antibodies
NO20082894L (no) Metode for behandling av kognitiv dysfunksjon
CR10297A (es) &#34;metodos para prevenir y tratar efermedades amiloidogenicas&#34;
MA32056B1 (fr) Suspension pharmaceutique orale contenant du paracetamol et de l&#39;ibuprofene
EA200971130A1 (ru) Агонисты гуанилатциклазы, пригодные для лечения желудочно-кишечных нарушений, воспаления, рака и других заболеваний
EP2029164A4 (fr) Thérapie de recrutement anti-leucocytaire pour le traitement de crises épileptiques et de l&#39;épilepsie
CR10730A (es) Anticuerpos agonistas anti notch3 y su uso en el tratamiento de las enfermedades relacionadas con el gen notch3
WO2008050329A3 (fr) NOUVEAUX ARNsi ET PROCÉDÉS D&#39;UTILISATION DE CEUX-CI
MX360150B (es) Antagonista del receptor de angiotensina ii para la prevencion o el tratamiento de enfermedades generalizadas en gatos.
MA33295B1 (fr) Nouvelle formulation de diclofénac
MA32684B1 (fr) Dérivés de picolinamide en tant qu&#39;inhibiteurs de kinase
EP2307032A4 (fr) Nouveaux conjugués de polymères sur lesquels sont fixés un agent thérapeutiquement actif et une fraction ciblant l&#39;angiogenèse et utilisations de ces conjugués pour traiter des maladies liées à l&#39;angiogenèse
EP2367561A4 (fr) Compositions et procédés pour le traitement d&#39;une maladie coeliaque
MA33724B1 (fr) Anticorps neutralisants anti-ngf humain en tant qu&#39;inhibiteurs selectifs de la voie du ngf
EP2047863A4 (fr) Prévention ou traitement d&#39;une maladie inflammatoire
EA200802412A1 (ru) Терапевтические комбинации для сопровождающихся болью медицинских состояний
EP2023950A4 (fr) Traitement du cancer par l&#39;urodilatine
ECSP099308A (es) Métodos de tratamiento de la depresión
TN2010000108A1 (fr) Traitement de symtomes vasomoteurs
EA200801244A1 (ru) Применение sdf-1 для лечения и/или профилактики неврологических заболеваний